1. Use information in the passage below and your own knowledge to answer the questions below.

In 2018 the US Food and Drug Administration and the European Medicines Agency approved two drugs that targeted mRNA molecules. These drugs were designed to treat a rare genetic disease that causes a blood protein produced by the liver to form clumps (amyloid deposits) in the cardiovascular system, digestive system and around nerve fibres. This disease called hereditary transthyretin (hATTR) amyloidosis affects about 50,000 people in the world. It is an autosomal dominant inherited condition that causes the mutation of the blood protein called transthyretin. The two drugs were designed to bind with the mRNA molecules.

Suggest why the two drugs could be used as a treatment for hereditary transthyretin (hATTR) amyloidosis.